Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients

Laura Ridolfi, Giammaria Fiorentini, Michele Guida, Maria Michiara, Andrea Freschi, Enrico Aitini, Michela Ballardini, Ettore Bichisao, Ruggero Ridolfi

Research output: Contribution to journalArticle

Abstract

The efficacy and tolerability of fotemustine, cisplatin, α-interferon and interleukin-2 biochemotherapy were evaluated in advanced melanoma patients. 'MU three times/week, every 3 weeks for six cycles. Sixty patients were evaluated for tumour response, 12 of whom had brain metastases (BM). One patient (1.7%) with BM achieved a complete response and partial responses were observed in 10 patients (16.7%), including one BM patient. Overall response rate was 18.4 and 16.6% in BM patients (median response duration 8.2 months). Disease control, defined as overall response and stable disease, was 58.4% in all patients and 75% in patients with BM. Median time to progression was 3.2 months (4.2 months in BM patients). Median overall survival was 8.9 months (7.6 months in BM patients). Toxic events were mild to moderate. This combination was well tolerated and showed acceptable clinical activity, especially in BM patients.

Original languageEnglish
Pages (from-to)100-105
Number of pages6
JournalMelanoma Research
Volume19
Issue number2
DOIs
Publication statusPublished - Apr 2009

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Dermatology

Fingerprint Dive into the research topics of 'Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients'. Together they form a unique fingerprint.

  • Cite this